Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
This study is currently recruiting participants.
Verified December 2012 by National Cancer Institute (NCI)
Study NCT01553149
Information provided by National Cancer Institute (NCI)
First Received on March 10, 2012.
Last Updated on December 5, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
